Amgen Inc
AMGN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000318154
In the last 90 days, Amgen Inc insiders filed 0 open-market purchases and 3 sales; 3,168 institutions reported holding it in 13F filings for Q2 2026, worth $161.7B in total; no superinvestor holds it.
Holders of 5% or more of AMGN
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Amgen Inc, largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 7.60%40.8M shares | – | Apr 17, 20251 filing | Apr 17, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
3 Schedule 13D and 13G filings on Amgen Inc, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 20263:43 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −10.00 ppfrom 10.00%Below 5% | Mar 13, 2026 | SEC |
| Sep 8, 202511:06 AM ET | Vanguard Group Inc | 13G/A | 10.00%53.9M shares | – | Aug 29, 2025 | SEC |
| Apr 17, 20259:35 AM ET | BlackRock, Inc. | 13G/A | 7.60%40.8M shares | – | Mar 31, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Amgen Inc shares.
No Form 144 notices for Amgen Inc are on file.